PHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com

Similar documents
Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig

Table 1 Hydrophilicity of MC and HPMC Grades. Polymer Cloud Point ( C) Hydrophilicity MC HPMC Type 2910 HPMC Type

To study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets.

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Evaluation of different binders for roller compaction R. Wang, W. Liu, T. Durig

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

Evaluation of Moisture Sorption Methods for Aqueous Moisture Barrier Coatings D. Tewari, R. Lewis, B. Kinsey and T. Dürig*

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1

DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ

Critical material properties for the design of robust drug products : excipient functionality related characteristics

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

Continuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016

SENTRY TM POLYOX Water Soluble Resins

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency

Adopting Technologies to Enhance Quality in Manufacturing

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

Folic Acid in Human Nutrition

Formulation development of Glipizide matrix tablet using different proportion of natural and semi synthetic polymers

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents

OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105

FORMULATION AND EVALUATION OF THEOPHYLLINE BILAYERED TABLETS USING HPC AS MATRIX MATERIAL

we ve got you covered pharmaceutical product and solution guide

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

METOLOSE: CONTENTS PAGE

International Journal of Research in Pharmacy and Science

Formulation and Evaluation

Klucel hydroxypropylcellulose. Physical and chemical properties

Available Online through Research Article

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

LYCOAT. New solutions for Film Coating from Roquette. LYCOAT for quicker quality coating

DEVELOPMENT AND IN VITRO EVALUATION OF SUSTAINED RELEASE FLOATING MATRIX TABLETS OF METFORMIN HYDROCHLORIDE

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

Journal of Chemical and Pharmaceutical Research

Dextrol and Strodex Surfactant Selection Guide

Eastman cellulose esters Pharmaceutical applications and drug delivery

Preparation and Evaluation of Gastro Retentive Floating Tablets of Atorvastatin Calcium

Volume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL

Design and In-vitro Evaluation of Silymarin Bilayer Tablets

Non-Food Uses of Polysaccharides

ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE

Formulation and Development of Sustained Release Tablets of Valsartan Sodium

Bahadur S. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,

Bioavailability enhancement of poorly soluble APIs. Enhanced solubilization out of solid glassy solutions prepared by Hot-Melt Extrusion

EUDRAGIT E 100, EUDRAGIT E PO and

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

EUDRAGIT L 100 and EUDRAGIT S 100

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

A study of compressibility and compactibility of directly compressible tableting materials containing tramadol hydrochloride

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

International Journal of Medicine and Pharmaceutical Research

MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY FLOATING APPROCHES

Effect of Polymer Concentration and Viscosity Grade on Atenolol Release from Gastric Floating Drug Delivery Systems

Preparation and In vitro Evaluation of Mucoadhesive Tablets of Montelukast Sodium

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5

FORMULATION AND EVALUATION OF BILAYERED TABLET OF METFORMIN HYDROCHLORIDE AND GLIMEPIRIDE

PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY

Kolliwax HCO. Technical Information. Hydrogenated castor oil powder for pharmaceutical use. = Registered trademark in many countries.

Application of IVIVCs in Formulation Development Douglas F Smith

Asian Journal of Research in Biological and Pharmaceutical Sciences

Journal of Chemical and Pharmaceutical Research

Design and Evaluation of Atenolol Floating Drug Delivery System

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

Formulation and In vitro Release Characterization of Metoprolol Succinate Extended Release Tablets

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

Design development and evaluation of citicoline controlled release tablets

Large scale production

( 12 ) Patent Application Publication ( 10 ) Pub. No.: US 2017 / A1

Virendra Singh et.al, IJPRR 2014; 3(11) 22

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

Experiences with USP Apparatus 4 Calibration

Development and Evaluation of Press Coated Tablet of Aceclofenac Shinde PV* and Mayee RV

Optimization of Glipizide sustained release matrix tablet formulation by central composite design- response surface methodology

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)

PQRI Workshop Bethesda 2012

Patel Krunal M et al. IRJP 2 (2)

PREPARATION AND INVITRO EVALUATION OF RABEPRAZOLE SODIUM DELAYED RELEASE ENTERIC COATED TABLETS

Formulation and evaluation of sustained release atenolol

Formulation and In-vitro Evaluation of Sumatriptan succinate Bilayer Tablets

International Journal of Innovative Pharmaceutical Sciences and Research

Cool Solutions for Hot Flushes

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING TABLETS OF FAMOTIDINE

Challenges in Developing Stable and Efficient Probiotic Formulations

ANNEXURE -2. Excipients profiles of Compritol ATO 888, Gelucire 43/01, HPMC and PVP and have been described in the following section.

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2010/39

Journal of Chemical and Pharmaceutical Research

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

RESEARCH ARTICLE. Darshanwar Varun.S.*,Jadhav S.B. Hambarde. S.K.

Sivakasi , Tamil Nadu, India. ABSTRACT KEYWORDS:

FORMULATION AND EVALUATION OF DILTIAZEM HYDROCHLORIDE COLON TARGETED TABLETS

Transcription:

PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-037-3 (Supersedes PTR-037-2) Page 1 of 7 Hydrodynamic Robustness of Hypromellose and Hydroxypropyl Cellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T. Dürig Abstract Summary Factors impacting the hydrodynamic robustness of hypromellose and hydroxypropylcellulose matrix systems were investigated using the USP III reciprocating apparatus. Drug release from systems with low (10%) polymer level, low drug solubility or erosion dependent release mechanisms were generally found to vary significantly with change in hydrodynamics. Introduction Recent studies indicate that the USP I (basket) and USP II (paddle) apparatus are often poorly predictive of in vivo release profiles, especially during the fed state, when a dosage form may be retained for 4-6 hours in the stomach, while continuously subjected to 3 to 4 contractions per minute. In contrast, the unconventional method of testing the modified release matrix tablets in the more hydrodynamically aggressive USP disintegration test was highly predictive of in vivo behavior (1). Hypromellose (HPMC) and hydroxypropyl cellulose (HPC) are widely used hydrophilic matrix polymers, however most published data on systems utilizing these two polymers is based on the conventional USP I or II dissolution apparatus. The current study aims to evaluate hydrodynamic robustness of HPMC and HPC matrix systems, taking polymer level, polymer molecular weight (MW) and drug solubility into account. As the disintegration test is not well suited for precise drug release studies on individual tablets, we chose the closely related USP III reciprocating cylinder dissolution apparatus. A variety of hydrodynamic conditions including the high shear, high fluid flow conditions of the disintegration test (as a model of fed state hydrodynamic conditions) as well as lower shear environments, more reflective of fasted state and intestinal hydrodynamic conditions were simulated by varying the reciprocation rate at 5, 15 and 25 dips per minute (dpm). Dissolution behavior in USP Apparatus I (basket) at 100 RPM was used as the reference and compared to USP Apparatus III at 5, 15 and 25 dips per minute (DPM), using the f2 similarity factor. Profiles with f2 values >50 are generally regarded as similar. Experimental Methods Table 1 lists the HPMC Type 2208 and HPC grades studied. Each polymer type was studied at two MW levels spanning intermediate (300-370 kda) to high MW (1000-1300 kda). Polymer loading was 10 and 30%. The model drugs were soluble theophylline (THEO, solubility 6.9mg/ml in ph 6.8 buffer at 37 C) and low soluble glipizide (GLIP, solubility 1.8 mg/ ml at ph 7.5 with 0.5% polysorbate 80 at 37 C). 400 mg Tablets comprising 25% drug (THEO or GLIP), 30% or 10% polymer (2 polymers at 2 molecular weights each), 0.5% magnesium stearate and q.s. microcrystalline cellulose were prepared by compression on a instrumented rotary tablet press. Hydrodynamic robustness was assessed based on similarity of dissolution profiles under different conditions, lack of erratic release patterns and low variability as measured by maximum standard deviation at individual dissolution time points. All statements, information and data presented herein are believed to be accurate and reliable, but are not to be taken as a guarantee, an express warranty, or an implied warranty of merchantability or fitness for a particular purpose, or representation, express or implied, for which Ashland and its subsidiaries assume legal responsibility. Registered trademark, Ashland or its subsidiaries, registered in various countries. Trademark, Ashland or its subsidiaries, registered in various countries. *Trademark owned by a third party. 2011, Ashland. Rev. 11-2011

Page 2 of 7 Table 1. Ashland Pharmaceutical Grade Cellulose Ether Polymers used in this Study. Grade Viscosity (mpa s) Nominal MW (kda) Benecel HPMC K4M PH CR 3,600 (a) 340 Benecel HPMC K100M PH CR 100,000 (a) 1000 Klucel HPC GXF 150-400 at 2% (b) 370 Klucel HPC HXF 1500-3000 at 1% (b) 1150 Results and Discussion (a) Viscosity measured according to EP Monograph (b) Viscosity measured according to USP Monograph General Observations: Factors which predispose a system toward diffusional release and minimize erosional contributions increase the likelihood of achieving a hydrodynamically robust system. These factors include high drug solubility and high gel strength, which can be achieved through increasing polymer MW and polymer loading. In contrast, lower MW and lower polymer loadings and lower drug solubility increase the erosional contributions to total drug release, leading to greater hydrodynamic sensitivity. Soluble Drug Dissolution, 30% Polymer Level: For soluble THEO, the USP I basket apparatus dissolution conditions at 100 rpm were generally similar to the USP III reciprocating cylinder apparatus at 5 dpm. Due to superior gel strength, formulations with 30% high MW HPC and HPMC were the most hydrodynamically robust, with no significant dissolution effect even at 25 dpm (Table 2 and Figures 1 and 2). In these systems drug is primarily released via diffusion through the hydrated gel matrix with negligible matrix erosion. High MW HPC had the longest release duration (t60% 14-15 hours). For high MW HPMC the t60% values varied form 9-11 hours depending on hydrodynamic conditions. Similarly, THEO formulations comprising 30% medium MW HPC or HPMC were hydro-dynamically robust up to 15 dpm, but release profiles accelerated markedly under extreme shear conditions of 25 dpm (f2 values <50). Figures 3 and 4 illustrate the dissolution behavior of Medium MW HPC and HPMC systems. Soluble Drug Dissolution, 10% Polymer Level: At low polymer levels, high MW HPC is not as effective as HPMC with t60% ranging from 3.5-4 hours as opposed to 5-6 hours for HPMC (Table 2 and Figures 1 and 2. At the 10% polymer level the variability of individual tablets increases markedly as hydrodynamic stress increases (Table 3). Low polymer loadings were also problematic for THEO formulations comprising intermediate MW polymer grades. Medium MW HPC was ineffective (t60% <1.5 hours under all dissolution conditions). For medium MW HPMC release times were longer, but extreme hydrodynamic sensitivity even at the lowest reciprocating cylinder frequency of 5 dpm was seen. (Table 3 and Figures 3 and 4). Based on these findings, 10% polymer levels should generally be avoided for soluble drugs. Insoluble Drug Dissolution, 30% level: With the exception of high MW HPC and HPMC at 30%, insoluble GLIP formulations were not as hydrodynamically robust as THEO formulations. However high MW HPMC and HPC at 30% are of limited use due to the physiologically unrealistically long dissolution times (t60%>>24 hours, Table 2). This can be attributed to the fact that erosion is required for GLIP release as diffusion alone is limited by low drug solubility. Medium MW HPC profiles were linear and had low variability under a specific hydrodynamic condition (Figure 5). This was not the case for medium MW HPMC which was more variable and erratic (Figure 6 and Table 3).

Page 3 of 7 Insoluble Drug Dissolution, 10% level: High MW HPC GLIP tablets were extremely sensitive to hydrodynamic changes even when switching from USP Apparatus I to USP Apparatus III at 5 dpm. (f2 = 39). 10% High MW HPMC was robust at 5 dpm, but release and variability in individual tablets markedly increased at 15 and 25 dpm. Medium MW HPC was ineffective at 10% polymer levels with t60% ranging from 0.25 to 1 hour ( Tables 2 and 3 and Figures 5 and 6). Conclusion Our study shows that low (10%) polymer levels were generally problematic for both soluble and insoluble drugs, resulting variably in insufficient release retardation, high variability or poor hydrodynamic robustness. At 30% polymer levels, hydrodynamically robust matrix tablets can be achieved for soluble drugs. However it was not possible to achieve hydrodynamic robustness beyond 5 dpm for low soluble, erosion dependent drug matrix systems, while simultaneously achieving release durations less than 24 hours. It is important to select dissolution conditions that provide physiologically relevant levels of shear, especially with respect to fed state conditions. The USP apparatus III set at 15 dpm appears highly suitable for this purpose. References (1) International Patent Application, WO 03/035029 A1. Louie-Helm, J. and Berner, B. May 2003. Table 2. Matrix Polymer, Polymer level and Hydrodynamic Effects on Drug Dissolution MW Polymer Type, Level High HPMC, 30% Medium HPMC, 30% High HPMC, 30% Medium HPMC, 30% T60% (Hrs) USP 1 100 RPM 5 DPM 15 DPM 25 DPM Theophylline 13 10 11 9 4 6 6 5 19 15.5 15.5 14 4 3.5 4 3.5 10 9 7.5 6 3 6 6 3.5 8 8 8 6 1.5 1 0.50 0.50 Glipizide >24 >24 >24 >24 24 19 12 9 >24 >24 >24 >24 >24 15.5 9 9 >24 >24 16 17 19 18.5 14 9 17.5 14.5 10 9 0.75 0.8 <0.25 <0.25 f2 Value (USP I, 100 RPM as Reference) 5 DPM 15 DPM 25 DPM 63 66 53 62 66 74 77 71 59 87 74 80 72 54 42 42 41 71 83 81 40 59 41 38 66 86 56 60 34 32 67 78 79 40 26 26 79 43 41 85 60 40 65 40 34 42 22 27 *f2 value in red indicate failure of the dissolution.

Page 4 of 7 Table 3. Matrix Polymer, Polymer Level and Hydrodynamic Effects on Variability of Individual Time Points Polymer USP 1 Maximum Standard Deviation MW Type, Level 100 RPM 5 DPM 15 DPM 25 DPM Theophylline High HPMC 30% 0.24 1.47 0.82 0.70 HPMC 10% 4.12 1.35 4.12 6.48 HPC 30% 1.44 1.38 0.57 0.39 HPC 10% 0.5 1.71 5.23 3.21 Medium HPMC 30% 1.86 1.10 3.17 2.31 HPMC 10% 7.15 2.82 1.59 4.20 HPC 30% 1.19 1.45 3.17 0.92 HPC 10% 3.63 2.46 6.04 1.73 Glipizide High HPMC 30% 3 0.93 2.66 3.03 HPMC 10% 2.95 4.00 1.63 4.25 HPC 30% 0.5 0.27 1.44 1.39 HPC 10% 1.0 2.26 4.34 2.78 Medium HPMC 30% 1.7 1.90 0.86 6.94 HPMC 10% 3.47 3.60 3.70 5.65 HPC 30% 4.76 7.81 0.84 2.90 HPC 10% 3.47 2.13 0.51 0.5 *S.D values in red indicate high standard deviation Figure 1. Effect of high MW HPC levels and hydrodynamics on release from soluble theophylline matrix tablets.

Page 5 of 7 Figure 2. Effect of high MW HPMC Type 2208 levels and hydrodynamics on release from soluble theophylline matrix tablets. Figure 3. Effect of medium MW HPC levels and hydrodynamics on release from soluble theophylline matrix tablets.

Page 6 of 7 Figure 4. Effect of medium MW HPMC levels and hydrodynamics on release from soluble theophylline matrix tablets. Figure 5. Effect of medium MW HPC levels and hydrodynamics on release from insoluble glipizide matrix tablets.

Figure 6. Effect of medium MW HPMC levels and hydrodynamics on release from insoluble glipizide matrix tablets. Page 7 of 7